We had the opportunity to work with the Biomarkers team at Medicines Discovery Catapult (MDC) to help them determine how to increase adoption of their services by the drug development community.

Our activities included:

• Obtaining insights via surveys and interviews with stakeholders working in academia, CROs, pharma/biotech, and venture capital

• Facilitating an advisory group meeting of prospective customers from the biomarker field

• Facilitating a strategic planning workshop for senior MDC stakeholders

• Supporting the development of a business case to increase investment in the biomarker service

These efforts provided valuable insights that enabled us to advise MDC on the value proposition and market for its biomarker services. The strategic planning meeting led to identification of the strategic issues to be addressed to increase adoption of MDC’s biomarker services. The outputs were used to develop a business case and pitch deck to bid for internal funding. We're pleased to share that this facilitated a positive decision, and our recommendations are being implemented to boost engagement. 

“My experience with Nexcea has been exceptional. They excelled in devising a structured plan for us to assess the value of integrating clinical biomarker analysis into our services at Medicines Discovery Catapult. In addition to assembling a thorough plan, they successfully coordinated interviews, facilitated an advisory group and constructed a comprehensive report containing decisive findings and recommendations for future steps.” 

Dr Gayle Marshall, Head of Biomarkers, Medicines Discovery Catapult